Influences of High-fiber, Organic Whole-food Formula on the Gut Microbiome in Critically Ill Children
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The gastrointestinal microbiome has been shown to be altered in critically-ill children such that there is a larger shift toward pathogenic bacteria. Previous studies have shown that probiotics, fecal transplants, antibiotic decontamination, and dietary interventions can shift the gastrointestinal microbiome toward a metabolically favorable microbiome profile and be associated with improvements in disease burden.
This study will randomize critically-ill children who are stable enough for enteral tube feedings to receive either Pediasure or Nourish. Pediasure is a commercially-made formula that is used commonly in pediatric patients. Nourish is an organic, whole-food formula with a high fiber content. High-fiber diets have been correlated with metabolically favorable microbiome profiles. This study will look at the microbiome before and after initiation of enteral tube feedings to determine if either formula is associated with a shift in the microbiome toward a favorable profile.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Justin Azar, MD
- Phone Number: 412-692-5833
- Email: justin.azar@chp.edu
Study Contact Backup
- Name: Michael Morowitz, MD
- Email: michael.morowitz@chp.edu
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15224
- Children's Hospital of Pittsburgh of UPMC
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Admitted to the pediatric intensive care unit
- Age 1-17 years old
- Previously placed enteric tube designed for enteric feeding
Exclusion Criteria:
- Vasoactive medication use
- History of allergies or intolerances to either Pediasure or Nourish
- Whey allergy or intolerance
- Gluten sensitivity or intolerance
- Medical condition that necessitate the use of specific formulas and/or nutritional needs (e.g. epilepsy requiring ketogenic diet, genetic metabolic dysfunction with specific formula requirements)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Pediasure
Patients assigned to this arm will receive Pediasure
|
The effects of Nourish on the gastrointestinal microbiome will be compared to the the effects of Pediasure on the gastrointestinal microbiome
|
|
Active Comparator: Nourish
Patients assigned to this arm will receive Nourish
|
The effects of Nourish on the gastrointestinal microbiome will be compared to the the effects of Pediasure on the gastrointestinal microbiome
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes to the gastrointestinal microbiome
Time Frame: Prior to initiation of enteral tube feeds then on day 1, day 5-7, and day 14 of feedings
|
Fecal samples will be collected for bacterial 16s rRNA gene sequencing and analysis
|
Prior to initiation of enteral tube feeds then on day 1, day 5-7, and day 14 of feedings
|
|
Changes to the gastrointestinal microbiome
Time Frame: Prior to initiation of enteral tube feeds then on day 1, day 5-7, and day 14 of feedings
|
Salivary samples will be collected for bacterial 16s rRNA gene sequencing and analysis
|
Prior to initiation of enteral tube feeds then on day 1, day 5-7, and day 14 of feedings
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Concentration of short-chain fatty acids
Time Frame: Prior to initiation of enteral tube feeds then on day 1, day 5-7, and day 14 of feedings
|
Fecal samples will be analyzed by gas chromatography
|
Prior to initiation of enteral tube feeds then on day 1, day 5-7, and day 14 of feedings
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Raj Aneja, MD, University of Pittsburgh Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms
- Disease Attributes
- Immune System Diseases
- Neoplasms by Histologic Type
- Hematologic Diseases
- Lymphatic Diseases
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Leukemia, Lymphoid
- Leukemia
- Pathological Conditions, Signs and Symptoms
- Hemic and Lymphatic Diseases
- Critical Illness
- Dysbiosis
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
Other Study ID Numbers
Other Study ID Numbers
- STUDY19080289
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Critical Illness
-
NCT07390773Not yet recruitingDecision Making | Neonatal Critical Illness | Pediatric Critical Illness
-
NCT05733975CompletedNeonatal Critical Illness | Pediatric Critical Illness
-
NCT07478367RecruitingCritical Illness Myopathy | Critical Illness Polyneuropathy | Critical Illness Polyneuromyopathy
-
NCT06006000RecruitingCritical Illness | Illness, Critical
-
NCT07345169RecruitingCritical Illness | Intensive Care Patients | Critical Illness Requiring Intensive Care - Sepsis | Critical Illness Requiring Intensive Care - Acute Brain Injury | Critical Illness Requiring Intensive Care - Major Surgery | Critical Illness Requiring Intensive Care - Polytrauma
-
NCT03223038CompletedPediatric Critical Illness
-
NCT02148081CompletedPediatric Critical Illness
-
NCT07462806Not yet recruitingPediatric Critical Illness
-
NCT04711070CompletedCritical Illness Myopathy | Myopathy Critical Illness
Clinical Trials on Pediasure
-
NCT01658267CompletedChildren | Under-nutrition
-
NCT00139451CompletedNutrition Disorders | Growth Disorders | Constitutional Growth Delay
-
NCT00561340Completed
-
NCT05088590CompletedHealthy Toddlers 12-36 Months of Age With Mild or Moderate Malnutrition
-
NCT00949117TerminatedLymphoma | Unspecified Childhood Solid Tumor, Protocol Specific | Myelodysplastic Syndromes | Leukemia | Malnutrition | Weight Changes